Understanding how the immune system responds to tuberculosis infection
Regulators of IFN-gamma responses during Mycobacterium tuberculosis infection
This study is looking at how a special protein called interferon gamma helps your immune system fight tuberculosis (TB), and it's for anyone interested in new ways to make TB treatment faster and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10875562 on NIH RePORTER |
What this research studies
This research investigates the immune responses to Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB). It focuses on the role of a specific cytokine, interferon gamma (IFNγ), in regulating immune responses and how it helps in controlling TB infection. By using advanced techniques like CRISPR to manipulate genes in immune cells, the researchers aim to uncover the mechanisms that enhance the immune system's ability to fight TB. The ultimate goal is to identify new therapeutic strategies that could shorten treatment duration and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis or those at high risk of developing the disease.
Not a fit: Patients with non-infectious diseases or those who do not have a history of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the treatment time for tuberculosis and enhance the immune response against the disease.
How similar studies have performed: Previous research has shown promising results in understanding immune responses to tuberculosis, but this specific approach using CRISPR technology is relatively novel.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Olive, Andrew — Michigan State University
- Study coordinator: Olive, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.